Eyepoint Pharmaceuticals Inc (EYPT)

Currency in USD
11.670
-0.750(-6.04%)
Closed·
11.864+0.194(+1.67%)
·
Earnings results expected today
Unusual trading volume
EYPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.54012.700
52 wk Range
9.51019.110
Key Statistics
Prev. Close
12.42
Open
12.44
Day's Range
11.54-12.7
52 wk Range
9.51-19.11
Volume
2.93M
Average Vol. (3m)
1.31M
1-Year Change
7.1625%
Book Value / Share
2.76
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EYPT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.500
Upside
+247.04%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 40.500
(+247.04% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Mizuho
Buy39.00+234.19%36.00MaintainJul 29, 2026
Stifel
Buy40.00+242.76%-New CoverageJul 15, 2026
Cantor Fitzgerald
Buy---New CoverageJul 08, 2026
Mizuho
Buy36.00+208.48%-MaintainJun 23, 2026
RBC Capital
Buy37.00+217.05%39.00MaintainMay 07, 2026

Eyepoint Pharmaceuticals Inc Earnings Call Summary for Q1/2026

  • EyePoint missed Q1 2026 forecasts with EPS of -$0.99 vs. -$0.82 expected; revenue fell 97.1% YoY to $0.7M as deferred revenue recognition ended.
  • Operating expenses rose 20.5% to $88M driven by Phase III trials for DURAVYU; net loss widened to $85M from $45M in Q1 2025.
  • Company maintains $223M cash position expected to fund operations through Q4 2027 without additional financing needs.
  • DURAVYU Phase III wet AMD data expected mid-2026; DME trial enrollment to complete Q3 2026 as company pursues first-in-class treatment status.
  • Stock rose 2.28% to $14.064 despite earnings miss, reflecting investor optimism about clinical pipeline despite high cash burn and regulatory risks.
Last Updated: 05/06/2026, 09:51 AM
Read Full Transcript

Earnings

Latest Release
May 06, 2026
EPS / Forecast
-0.99 / -0.82
Revenue / Forecast
696K / 1.01M
EPS Revisions
Last 90 days

EYPT Income Statement

Compare EYPT to Peers and Sector

Metrics to compare
EYPT
Peers
Sector
Relationship
P/E Ratio
−3.6x−4.1x−0.4x
PEG Ratio
0.09−0.190.00
Price / Book
4.2x1.2x2.6x
Price / LTM Sales
128.5x2.3x3.0x
Upside (Analyst Target)
206.0%24.2%51.9%
Fair Value Upside
Unlock29.1%7.2%Unlock

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
31.22M37.23%387.72M
Other Institutional Investors
77.74M62.77%965.48M
Public Companies & Retail Investors
0.000.00%0.00
Total
108.95M100.00%1.35B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Montanova Capital, LLC9.90%8,296,375103,041
Cormorant Asset Management, LP9.86%8,265,000102,651

People Also Watch

8.57
POET
+16.44%
20.84
VRDN
+7.92%
125.33
SPCX
+9.43%
1.570
CRBU
+4.67%
13.480
SPIR
+9.77%

FAQ

What Is the Eyepoint Pharma (EYPT) Stock Price Today?

The Eyepoint Pharma stock price today is 11.670 USD.

What Stock Exchange Does Eyepoint Pharma Trade On?

Eyepoint Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Eyepoint Pharma?

The stock symbol for Eyepoint Pharma is "EYPT."

What Is the Eyepoint Pharma Market Cap?

As of today, Eyepoint Pharma market cap is 978.430M USD.

What Is Eyepoint Pharma's Earnings Per Share (TTM)?

The Eyepoint Pharma EPS (TTM) is -3.513.

When Is the Next Eyepoint Pharma Earnings Date?

Eyepoint Pharma will release its next earnings report on Aug 05, 2026.

From a Technical Analysis Perspective, Is EYPT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Eyepoint Pharma Stock Split?

Eyepoint Pharma has split 2 times.

What is the current trading status of Eyepoint Pharma (EYPT)?

As of Aug 05, 2026, Eyepoint Pharma (EYPT) is trading at a price of 11.670 USD, with a previous close of 12.420 USD. The stock has fluctuated within a day range of 11.540 USD to 12.700 USD, while its 52-week range spans from 9.510 USD to 19.110 USD.

What Is Eyepoint Pharma (EYPT) Price Target According to Analysts?

The average 12-month price target for Eyepoint Pharma is 40.500 USD, with a high estimate of 68 USD and a low estimate of 20 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +247.04% Upside potential.

What Is the EYPT Premarket Price?

EYPT's last pre-market stock price is 12.150 USD. The pre-market share volume is 800.000, and the stock has decreased by -0.270, or -2.170%.

What Is the EYPT After Hours Price?

EYPT's last after hours stock price is 11.864 USD, the stock has decreased by 0.194, or 1.670%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.